<DOC>
	<DOCNO>NCT02717806</DOCNO>
	<brief_summary>The PATHway system design help patient remain physically active maintain good cardiovascular health . It propose novel approach aim empower patient self-manage CVD , set within collaborative care context health professional . This achieved via patient-centric holistic approach specifically address barrier . It involve internet-enabled sensor-based home exercise platform . It represent several module exercise module core component provide individualize rehabilitation program use regular , socially inclusive exercise session basis upon provide personalize , comprehensive lifestyle intervention program ( manage exercise , smoking , diet , stress , alcohol use etc . ) enable patient well understand deal condition lead healthier lifestyle general . The goal trial ass acceptability , short-term effectiveness lifestyle health related physical fitness cost-effectiveness PATHway intervention patient CVD single blind multicentre pilot randomise control trial ( RCT ) .</brief_summary>
	<brief_title>Technology-enabled Cardiac Rehabilitation Through PATHway . Feasibility , Clinical Effectiveness Cost-effectiveness</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Men woman document CVD age 4080 yr patient optimal medical treatment stable regard symptom pharmacotherapy least 4 week patient must complete ambulatory CR program receive clinical approval treat physician continue exercise outside hospital program internet access home significant illness last 6 week know severe ventricular arrhythmia functional prognostic significance significant myocardial ischemia , hemodynamic deterioration exerciseinduced arrhythmia baseline test cardiac disease limit exercise tolerance ( valve disease significant hemodynamic consequence , hypertrophic cardiomyopathy etc . ) comorbidity may significantly influence oneyear prognosis functional mental disability may limit exercise acute chronic inflammatory disease malignancy , use antiinflammatory drug immune suppression GFR &lt; 25ml/min/1.73m2 hemoglobin &lt; 10g/dl severe chronic obstructive pulmonary disease ( FEV1 &lt; 50 % ) NYHA class 4 participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>